Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity.

ABSTRACT:

Importance

Despite the clinical benefits of treating obesity and related complications, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are not yet covered by Medicare Part D, partly due to high drug costs. The Biden administration's proposal to expand Part D coverage underscores the need to assess the balance between fiscal costs and benefits to guide policy decisions.

Objective

To estimate the 10-year net fiscal impact of expanded Medicare coverage for GLP-1RAs for obesity treatment.

Design, setting, and participants

In this economic evaluation, a 10-year fiscal impact analysis was conducted between 2026 and 2035 using the validated Diabetes, Obesity, Cardiovascular Disease Microsimulation model. The base-case analysis incorporated a 10% 1-time uptake rate for

SUBMITTER: Hwang JH 

PROVIDER: S-EPMC12032556 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature